Cohort 1: bococizumab 150 mg + rHuPH20
B1481051
Phase 1 mab terminated
Quick answer
Cohort 1: bococizumab 150 mg + rHuPH20 for Healthy is a Phase 1 program (mab) at HALOZYME THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- HALOZYME THERAPEUTICS, INC.
- Indication
- Healthy
- Phase
- Phase 1
- Modality
- mab
- Status
- terminated